Clinical Trial Phases Explained for Weight-Loss Drugs

When a new obesity medicine makes headlines, the trial phase tells you how far the evidence has come. A Phase 1 result isn't a small preview of an approval; it answers a completely different question from a Phase 3 trial. Knowing the difference helps you tell an early signal from a solid body of evidence.

The phases at a glance

The FDA gives these typical ranges (real trials vary):

Phase	Typical size	Typical length	Main purpose
Phase 1	20–100 people	Several months	Safety and dosage
Phase 2	Up to several hundred	Several months to 2 years	Effectiveness and side effects
Phase 3	300–3,000	1–4 years	Effectiveness and monitoring of adverse reactions
Phase 4	Several thousand	After approval	Ongoing safety and effectiveness

The FDA also estimates that only about 25–30% of drugs that reach Phase 3 move on to the next stage, which is a good reminder that promising early results don't always hold up.

Phase 1: is it safe to keep going?

Early studies are small and focus on tolerability, dose ranges and how the body absorbs and clears the drug. They help researchers plan the next step, but they're not designed to prove long-term weight loss or catch rare side effects.

Phase 2: is there a real signal?

Phase 2 trials test the drug in people with the condition and explore which doses work and what side effects appear. Retatrutide is a good example: its Phase 2 trial enrolled 338 adults with obesity or overweight for 48 weeks and tested several doses. Results like these guide the next trial, but they may not be repeated at scale, and a press release may spotlight the best-performing dose.

Phase 3: does it hold up in a bigger group?

Phase 3 trials enroll more people for longer. Retatrutide's TRIUMPH-1 trial, published in September 2026, followed 2,339 adults for 80 weeks. Design details shape the result: the comparator (placebo or another drug), the doses, who was eligible, how dropouts were handled and what outcomes were measured.

One detail worth knowing is the estimand, meaning how a trial counts people who stop treatment. A "treatment-regimen" or intention-to-treat result counts everyone who started; an "efficacy" result estimates what happens if everyone stayed on the drug, which usually looks larger. In TRIUMPH-1, the main analysis showed an average weight change of −25.0% at the 12 mg dose, while Lilly's press release highlighted up to −28.3% from the efficacy analysis. Both are real numbers; they answer different questions. We dig into this in retatrutide's 2026 trial results.

A positive Phase 3 still isn't approval. Regulators review all the data plus manufacturing before deciding on a label. Foundayo (orforglipron), for example, was approved by the FDA on April 1, 2026, after Phase 3 trials, while retatrutide remains investigational as of October 2026.

Phase 4: what happens after approval?

Once a medicine is on the market, studies and safety monitoring continue in far more people. Rare side effects, or benefits in new groups, can emerge only at this stage.

How to read a drug headline

Ask: is this a peer-reviewed paper, a conference presentation or a company topline announcement? Was the drug compared with placebo or an active medicine? How long did the trial last, and who was in it? Which analysis does the number come from? Company announcements are useful, but they're sponsor-reported until the full data are published.

And keep the line between science and treatment clear: never buy an investigational medicine online or follow a dosing schedule from a trial abstract. Here's more on why investigational drugs aren't the same as approved medicines.

Trial phases are a roadmap for evidence, not a scorecard telling you which future medicine will work best for you.